Virus-like particle vaccine containing the F protein of respiratory syncytial virus confers protection without pulmonary disease by modulating specific subsets of dendritic cells and effector T cells

Journal of Virology

Volumn 89, Issue 22, 2015, Pages 11692-11705

  Kim, Ki Hye ^a   Lee, Young Tae ^a   Hwang, Hye Suk ^a   Kwon, Young Man ^a   Kim, Min Chul ^a,b   Ko, Eun Ju ^a   Lee, Jong Seok ^a,c   Lee, Youri ^a   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^c National Institute of Biological Resources   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD11B ANTIGEN; CD8 ANTIGEN; CD8ALPHA ANTIGEN; F PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; INACTIVATED VACCINE; INTERLEUKIN 4; LIVE VACCINE; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN; ALPHA E INTEGRINS; ALPHA INTEGRIN; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; LEUKOCYTE ANTIGEN; TUMOR NECROSIS FACTOR; VIRUS FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD103+ DENDRITIC CELL; CD11B+ DENDRITIC CELL; CD4+ T LYMPHOCYTE; CD8ALPHA+ DENDRITIC CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; EFFECTOR CELL; EOSINOPHILIA; F SPECIFIC INTERFERON GAMMA+ T CELL; FEMALE; HISTOPATHOLOGY; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION; IMMUNOMODULATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; T LYMPHOCYTE; TUMOR NECROSIS FACTOR ALPHA+ CD8+ T LYMPHOCYTE; VIRAL CLEARANCE; VIRUS DETECTION; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CD8+ T LYMPHOCYTE; CELL LINE; HUMAN; IMMUNOLOGY; LUNG; LUNG DISEASE; METABOLISM; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SF9 CELL LINE; SPODOPTERA; TH1 CELL; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNIZATION; INTEGRIN ALPHA CHAINS; INTERFERON-GAMMA; INTERLEUKIN-4; LUNG; LUNG DISEASES; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SF9 CELLS; SPODOPTERA; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS; VIRAL LOAD;

EID: 84945922790     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02018-15     Document Type: Article

References (42)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
2. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89:422-434.
3. Castilow EM, Olson MR, Varga SM. 2007. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunologic research 39:225-239. http://dx.doi.org/10.1007/s12026-007-0071-6.
4. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, III, Murphy BR. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSVimmunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68:5321-5325.
5. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. 1996. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70: 2852-2860.
6. Henderson FW, Collier AM, Clyde WA, Jr., Denny FW. 1979. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 300:530-534.
7. Hall CB, Douglas RG, Jr, Simons RL, Geiman JM. 1978. Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr 93:28-32. http://dx.doi.org/10.1016/S0022-3476(78)80594-0.
8. Hall CB, Walsh EE, Long CE, Schnabel KC. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163: 693-698. http://dx.doi.org/10.1093/infdis/163.4.693.
9. McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG. 2011. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 85:366-377. http://dx.doi.org/10.1128/JVI.01861-10.
10. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG. 2010. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 84:1110-1123. http://dx.doi.org/10.1128/JVI.01709-09.
11. Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, Moore ML, Compans RW. 2011. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 204:987-995. http://dx.doi.org/10.1093/infdis/jir474.
12. Lee S, Quan FS, Kwon Y, Sakamoto K, Kang SM, Compans RW, Moore ML. 2014. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins. Antivir Res 111:129-135. http://dx.doi.org/10.1016/j.antiviral.2014.09.005.
13. Hwang HS, Kwon YM, Lee JS, Yoo SE, Lee YN, Ko EJ, Kim MC, Cho MK, Lee YT, Jung YJ, Lee JY, Li JD, Kang SM. 2014. Coimmunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antivir Res 110:115-123. http://dx.doi.org/10.1016/j.antiviral.2014.07.016.
14. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796. http://dx.doi.org/10.1128/JVI.00555-11.
15. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, et al. 1992. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 73(Pt 9):2225-2234. http://dx.doi.org/10.1099/0022-1317-73-9-2225.
16. Beeler JA, van Wyke Coelingh K. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63:2941-2950.
17. Prince GA, Curtis SJ, Yim KC, Porter DD. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with lot 100 or a newly prepared reference vaccine. J Gen Virol 82:2881-2888. http://dx.doi.org/10.1099/0022-1317-82-12-2881.
18. Kwon YM, Hwang HS, Lee JS, Ko EJ, Yoo SE, Kim MC, Lee YN, Kim KH, Song JM, Lee S, Moore ML, Kang SM. 2014. Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antivir Res 104: 1-6. http://dx.doi.org/10.1016/j.antiviral.2014.01.008.
19. Jiang S, Borthwick NJ, Morrison P, Gao GF, Steward MW. 2002. Virus-specific CTL responses induced by an H-2K(d)-restricted, motifnegative 15-mer peptide from the fusion protein of respiratory syncytial virus. J Gen Virol 83:429-438. http://dx.doi.org/10.1099/0022-1317-83-2-429.
20. Olson MR, Varga SM. 2008. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines 7:1239-1255. http://dx.doi.org/10.1586/14760584.7.8.1239.
21. + dendritic cells. Nat Immunol 10:488-495. http://dx.doi.org/10.1038/ni.1724.
22. + dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol 170:4437-4440. http://dx.doi.org/10.4049/jimmunol.170.9.4437.
23. + dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 172: 1996-2000. http://dx.doi.org/10.4049/jimmunol.172.4.1996.
24. Lukens MV, Kruijsen D, Coenjaerts FE, Kimpen JL, van Bleek GM. 2009. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lungdraining lymph node. J Virol 83:7235-7243. http://dx.doi.org/10.1128/JVI.00452-09.
25. Graham BS, Bunton LA, Wright PF, Karzon DT. 1991. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88:1026-1033. http://dx.doi.org/10.1172/JCI115362.
26. Boelen A, Andeweg A, Kwakkel J, Lokhorst W, Bestebroer T, Dormans J, Kimman T. 2000. Both immunization with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 19:982-991. http://dx.doi.org/10.1016/S0264-410X(00)00213-9.
27. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM. 1986. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 57:721-728.
28. Johnson TR, Teng MN, Collins PL, Graham BS. 2004. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccineenhanced disease induced by immunization with formalin-inactivated RSV. J Virol 78:6024-6032. http://dx.doi.org/10.1128/JVI.78.11.6024-6032.2004.
29. Johnson TR, Graham BS. 2004. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr Infect Dis J 23:S46-S57. http://dx.doi.org/10.1097/01.inf.0000108192.94692.d2.
30. Johnson TR, Graham BS. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 73:8485-8495.
31. Tang YW, Graham BS. 1994. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest 94:1953-1958. http://dx.doi.org/10.1172/JCI117546.
32. Castilow EM, Olson MR, Meyerholz DK, Varga SM. 2008. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J Virol 82:2196-2207. http://dx.doi.org/10.1128/JVI.01949-07.
33. Christiaansen AF, Knudson CJ, Weiss KA, Varga SM. 2014. The CD4 T cell response to respiratory syncytial virus infection. Immunol Res 59: 109-117. http://dx.doi.org/10.1007/s12026-014-8540-1.
34. Pulendran B. 2004. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199:227-250. http://dx.doi.org/10.1111/j.0105-2896.2004.00144.x.
35. Stumbles PA, Thomas JA, Pimm CL, Lee PT, Venaille TJ, Proksch S, Holt PG. 1998. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J Exp Med 188:2019-2031. http://dx.doi.org/10.1084/jem.188.11.2019.
36. Dodge IL, Carr MW, Cernadas M, Brenner MB. 2003. IL-6 production by pulmonary dendritic cells impedes Th1 immune responses. J Immunol 170:4457-4464. http://dx.doi.org/10.4049/jimmunol.170.9.4457.
37. Castilow EM, Legge KL, Varga SM. 2008. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J Immunol 181:6692-6696. http://dx.doi.org/10.4049/jimmunol.181.10.6692.
38. Ostler T, Ehl S. 2002. Pulmonary T cells induced by respiratory syncytial virus are functional and can make an important contribution to long-lived protective immunity. Eur J Immunol 32:2562-2569. http://dx.doi.org/10.1002/1521-4141(200209)32:9<2562::AID-IMMU2562>3.0.CO;2-4.
39. + T cell responses. J Immunol 166: 1106-1113. http://dx.doi.org/10.4049/jimmunol.166.2.1106.
40. Zeng R, Cui Y, Hai Y, Liu Y. 2012. Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines. Virus Res 167: 138-145. http://dx.doi.org/10.1016/j.virusres.2012.06.003.
41. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2:732-738. http://dx.doi.org/10.1038/90675.
42. Haynes LM, Jones LP, Barskey A, Anderson LJ, Tripp RA. 2003. Enhanced disease and pulmonary eosinophilia associated with formalininactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol 77:9831-9844. http://dx.doi.org/10.1128/JVI.77.18.9831-9844.2003.